BRISTOL-MYERS SQUIBB COMPANY Long-Term Debt, Maturity, Year Five
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Long-Term Debt, Maturity, Year Five of $2.10 billion as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-02-11
- 2025-12-31: Long-Term Debt, Maturity, Year Five $2.10B.
- 2024-12-31: Long-Term Debt, Maturity, Year Five $4.20B.
- 2023-12-31: Long-Term Debt, Maturity, Year Five $1.50B.
- 2013-12-31: Long-Term Debt, Maturity, Year Five $631.00M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $2.10B 10-K · filed 2026-02-11 |
| 2024-12-31 | $4.20B 10-K · filed 2025-02-12 |
| 2023-12-31 | $1.50B 10-K · filed 2024-02-13 |
| 2013-12-31 | $631.00M 10-K · filed 2014-02-14 |
| 2012-12-31 | $750.00M 10-K · filed 2013-02-15 |
| 2011-12-31 | $652.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |